8,068 reports of this reaction
3.5% of all DIMETHYL FUMARATE reports
#4 most reported adverse reaction
MULTIPLE SCLEROSIS RELAPSE is the #4 most commonly reported adverse reaction for DIMETHYL FUMARATE, manufactured by Biogen Inc.. There are 8,068 FDA adverse event reports linking DIMETHYL FUMARATE to MULTIPLE SCLEROSIS RELAPSE. This represents approximately 3.5% of all 232,901 adverse event reports for this drug.
Patients taking DIMETHYL FUMARATE who experience multiple sclerosis relapse should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
MULTIPLE SCLEROSIS RELAPSE is moderately reported among DIMETHYL FUMARATE users, representing a notable but not dominant share of adverse events.
In addition to multiple sclerosis relapse, the following adverse reactions have been reported for DIMETHYL FUMARATE:
The following drugs have also been linked to multiple sclerosis relapse in FDA adverse event reports:
MULTIPLE SCLEROSIS RELAPSE has been reported as an adverse event in 8,068 FDA reports for DIMETHYL FUMARATE. This does not prove causation, but indicates an association observed in post-market surveillance data.
MULTIPLE SCLEROSIS RELAPSE accounts for approximately 3.5% of all adverse event reports for DIMETHYL FUMARATE, making it a notable side effect.
If you experience multiple sclerosis relapse while taking DIMETHYL FUMARATE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.